Categories: Wire Stories

First Healthy Volunteer Dosed in Symvivo�s Phase 1 Clinical Trial of bacTRL-Spike�, an Oral COVID-19 Vaccine Candidate

BURNABY, British Columbia–(BUSINESS WIRE)–Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL� gene delivery platform, today announced the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19.

“We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for future clinical development,” said Eric Sievers, MD, Chief Medical Officer of Symvivo Corporation. “The rapidly advancing pandemic mandates innovative scientific approaches and we believe a safe, protective oral vaccine could transform the landscape of traditional vaccination approaches, eliminating the need for syringes, needles, and trained vaccinators.”

The Phase 1 trial, Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike™ Vaccine for Prevention of COVID-19 (NCT04334980), is being conducted in partnership with Nucleus Network in Brisbane, Australia. Associate Professor Paul Griffin, infectious diseases physician and microbiologist at Nucleus Network, is the primary investigator. The study will evaluate safety and preliminary evidence of immunogenicity to SARS CoV-2 elicited by bacTRL-Spike™ among healthy volunteers. Preliminary data are anticipated in early 2021.

Unlike traditional vaccines that are delivered by intramuscular injection, bacTRL-Spike™ is taken orally, providing the potential for individuals to self-administer the vaccine rather than requiring a trained medical professional.

About Symvivo

Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases. Symvivo’s bacTRL™ platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient’s own cells to produce therapeutic proteins. Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology (NCT04025307), immunology and protein therapy. Symvivo is headquartered in Burnaby, British Columbia. For more information, visit www.symvivo.com.

Contacts

Canadian Media:
Chantal Allan

Sam Brown Inc. Healthcare Communications

T: 613-319-4384 (CAN)

T: 805-242-3080 (US)

E: chantalallan@sambrown.com

US Media:
Mike Beyer

Sam Brown Inc. Healthcare Communications

T: 312-961-2502

E: mikebeyer@sambrown.com

Alex

Recent Posts

CGTN: China vows continued efforts to build Asia-Pacific community with shared future

BEIJING, CHINA - Media OutReach Newswire - 8 November 2024 - Since its inception more…

3 hours ago

TBS Energi Utama to Acquire Singapore’s Integrated Waste Management Services Provider, Sembcorp Environment Pte. Ltd.

Acquisition Expands TBS’ Regional Waste Management Platform in Indonesia and Singapore, aligning with its TBS2030…

4 hours ago

Score 11 Unbeatable Deals This 11.11 on Shopee with 90% Off Lowest Price Guaranteed

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 8 November 2024 - It’s that time…

6 hours ago

Shenzhen China Wins the World Smart City Award, Demonstrating the Global Influence of Social Intelligent Governance of Mega City

BARCELONA, SPAIN - Media OutReach Newswire - 8 November 2024 - On November 6, Central…

7 hours ago

Singapore – A Trusted Global Supply Chain Management Hub

SINGAPORE - Media OutReach Newswire - 8 November 2024 - Singapore is strengthening its position…

9 hours ago

OPPO Celebrates Global Photography Talent at Paris Photo Fair under the theme of “Dear Life”

PARIS, FRANCE - Media OutReach Newswire – 8 November 2024 - This year, OPPO once…

9 hours ago